Inhibition of miR-17 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Time: 9:30 am
day: Day Two


  • Investigating preclinical data supporting miR-17 as therapeutic target for ADPKD
  • Assessing translational research leading up to the development of clinically-relevant urinary biomarker for ADPKD
  • Exploring clinical data demonstrating target engagement and proof of mechanism in ADPKD patients